Recent research indicated that Eladis® exhibited overall effectiveness and a statistically significant superiority compared to the placebo. The data from this study were presented in the journal Terapevticheskii arkhiv.

This phase III clinical trial enrolled 250 individuals aged 18 to 65 years suffering from acute respiratory viral infections with acute bronchitis or upper respiratory tract involvement. Participants were randomly assigned into two groups of 125: one group received Eladis® (40 mg tablets), while the other group received a placebo. The study drugs were administered as one tablet twice daily for a duration of seven to fourteen days. Following the treatment, patients were followed up (on day 7±2) to evaluate the therapy effects on the frequency and intensity of daytime and nighttime cough, the frequency of coughing episodes, the severity of cough, the duration until clinical resolution of cough, and the effect on the severity of the main symptoms associated with acute respiratory viral infections.

Significant differences were observed among the study groups in the percentage of patients who achieved a reduction in coughing attack frequency by 50% or more by day five (p value <0.0001). Additionally, the Eladis® group demonstrated clinical resolution of cough two days earlier, with a median time of six days compared to eight days in the placebo group. By day five of treatment, there was a substantial decrease in both the frequency and severity of cough attacks, exceeding 3.5 points. All these effects were correlated with the drug's high safety profile.

Therefore, Eladis® demonstrated overall efficacy and a statistically significant benefit in comparison to the placebo.

A new study demonstrated that patients who have been catheterized due to acute urinary retention secondary to benign prostatic hyperplasia (AUR Secondary to BPH) may experience spontaneous voiding after catheter removal if they are treated with silodosin, regardless of the duration of catheterization. However, side effects tend to increase with longer periods of catheterization. This study’s findings were published in the journal, Urologia.

The study included 260 patients who experienced acute urinary retention secondary to benign prostatic hyperplasia. The patients underwent catheterization and were subsequently allocated at random to receive either 8 mg of silodosin for a period of three days or seven days. After the treatment period, the catheter was removed, and the success of voiding unaided was evaluated.

Out of the 260 men who were treated, 74 men who were on a 3-day silodosin regimen and 88 patients who were on a 7-day silodosin regimen did not require re-catheterization on the day of outcome of trial without catheter (TWOC) (57% and 68% respectively). In the group of participants who underwent the 3-day silodosin regimen, 16.2% experienced complications like acute urinary tract infection, urinary leakage, hematuria, or catheter blockage. On the other hand, in the group that received the 7-day silodosin treatment, 48.5% reported similar issues.

Therefore, silodosin treatment demonstrated positive outcomes in patients who have undergone catheterization as a result of AUR secondary to BPH. Irrespective of the duration of catheterization, these patients can spontaneously void after the removal of the catheter if they are treated with silodosin. It is important to consider that the likelihood of experiencing side effects tends to increase with longer periods of catheterization.

A recent study showed that sublingual immunotherapy (SLIT) has the potential to be an optimal  adjuvant therapy post-septomeatoplasty (SMP) for individuals suffering from allergic rhinitis (AR). This study’s findings were published in The Laryngoscope.

This study included 96 patients diagnosed with allergic rhinitis caused by dust mites, in addition to concurrent septal deviation and hypertrophy of the inferior turbinate. All patients underwent surgical intervention (SMP). Subsequently, the patients were divided into two groups: the control group (n=44), who underwent surgery alone, and the SMP+SLIT group (n=52), who were given SLIT as an adjuvant therapy. The results of the rhinitis control assessment test (RCAT) and the demographic data were analyzed.

No significant differences were noted in any of the variables between the two groups before and 1^st month after surgery. However, at the 3^rd and 6^th  month assessments, the SMP + SLIT group demonstrated a significant enhancement in the total RCAT scores in comparison to the SMP only group (28.6 ± 1.56 versus 24.5 ± 3.66, p < 0.001, 27.1 ± 2.87 versus 19.9 ± 5.56, p < 0.001). Additionally, superior control of all RCAT sub-categories was noted in the SMP + SLIT group during the 3^rd  and 6^th month evaluations.

In conclusion, SLIT could potentially function as a beneficial adjuvant treatment following SMP for individuals suffering from AR.

According to a recent study, low-level laser therapy (LLLT) and low-intensity pulsed ultrasound (LIPUS) effectively reduced separation pain when applied in multiple doses during orthodontic treatment. The results of this study were published in the journal, BMC Oral Health.

150 patients were randomly assigned to three groups in this single-blind, randomized controlled trial: the LLLT group, the LIPUS group, and the control group. The first dose of the laser or ultrasound was applied 5 min from the separators' placement, second dose was given after 24 h, and the last dose was administered on both maxillary and mandibular first molars after 48 h. The patients were exposed to the laser for 20 s, using an 810-nm aluminum-gallium-arsenide (AlGaAs) diode laser on continuous mode. For 20 minutes, 1.6 MHz ultrasonic toothbrush treatment was applied (5 minutes for each first molar). The control group was administered the separator without any other intervention. Pain intensity was assessed at several time intervals during the first four days post the separator’s placement, using a Visual Analog Scale (VAS 100 mm).

It was found after assessing 145 patients that a significant difference in pain perception was observed among the three groups after 5 min. Pain level reached its maximum intensity after 24 h. All the assessment time points showed a statistically significant decrease in pain scores for both the laser and the ultrasound groups when compared to the control group. Moreover, the laser and ultrasound group showed no difference between them in terms of reducing the pain scores.

Hence, it can be concluded that LLLT and the LIPUS may effectively reduce the separation pain experienced during orthodontic treatment after the application of multiple doses, without any difference between them.

A recent study found that R21/Matrix-M vaccine which is low-cost, was well tolerated and offered high efficacy against clinical malaria in children. The results of this study were published in the journal, Lancet.

This double-blind, randomised, phase 3 trial of the R21/Matrix-M malaria vaccine screened 5477 children (aged 5-36 months), out of which 1705 and 3434 children were randomly assigned in a 2:1 ratio to the control vaccine and R21/Matrix-M (5 μg R21 plus 50 μg Matrix-M), respectively. The vaccines were administered 4 weeks apart as 3 doses, with a booster dose administered 12 months after the third dose. Half of the participants were recruited at the seasonal malaria transmission sites and the other half at standard sites with perennial malaria transmission. The primary objective of the study was to assess the protective efficacy of R21/Matrix-M, 14 days following the third vaccination. Vaccine efficacy, safety, and immunogenicity were also assessed.

At the end of the study, it was found that R21/Matrix-M vaccine was well tolerated. The most frequent adverse events were injection site pain (301 out of 1615 participants) and fever (754 out of 1615 participants). At the end of 12 months, the vaccine efficacy at the seasonal sites and standard sites were 75% and 67%, respectively. The effectiveness of the vaccine was correlated with antibodies produced by the vaccination against the conserved central Asn-Ala-Asn-Pro (NANP) repeat sequence of the circumsporozoite protein. The 5-17 month age group of children showed higher NANP-specific antibody titres when compared to the 18-36 month age group.

From the above results, it can be concluded that R21/Matrix-M vaccine which is low-cost, may be well tolerated and may offer high efficacy against clinical malaria in children.